Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592626 · ClinicalTrials.gov registry record · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
A Phase 1 study of Neoplasms and Advanced Solid Tumors, sponsored by Marengo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 365
- Enrollment target
- 20
- Study locations
NCT05592626: Recruiting Phase 1 study of Neoplasms and Advanced Solid Tumors, sponsored by Marengo Therapeutics.
NCT05592626 is a Phase 1 study of Neoplasms and Advanced Solid Tumors that is actively recruiting participants, run by Marengo Therapeutics. The registered enrollment target is 365 participants, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05592626, a Phase 1 study of Neoplasms and Advanced Solid Tumors, is actively recruiting participants, sponsored by Marengo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 365 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
Conditions Studied
Interventions
- DRUG STAR0602
Study Locations (20)
California
- Loma Linda University Cancer Center - Loma Linda
- UC Davis Comprehensive Cancer Center - Sacramento
Florida
- AdventHealth Celebration - Celebration
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
Texas
- The University of Texas, MD Anderson Cancer Center - Houston
- UT Health Mays Cancer Center - San Antonio
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Kansas
- The University of Kansas Cancer Center - Kansas City
Maryland
- National Institutes of Health - Bethesda
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2023-01-04 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
What NCT05592626 shows while recruiting
NCT05592626 is an interventional study that assigns participants to a tested intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap, below the 1,619-participant average among 158 other Neoplasms trials with a reported enrollment target (77% lower).
The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which STAR0602 is the first listed.
NCT05592626 names 20 study sites across 16 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05592626 about?
NCT05592626 is a clinical study titled "A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors". This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.
What is the current status of trial NCT05592626?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 365 participants. The study started on 2023-01-04. Estimated completion is 2026-10.
What conditions does trial NCT05592626 study?
This clinical trial studies the following conditions: Neoplasms, Advanced Solid Tumors, Carcinoma, Neoplasms by Site, Urogenital Neoplasms.
What interventions are being tested in trial NCT05592626?
The interventions under investigation include: STAR0602 (DRUG).
Who is sponsoring clinical trial NCT05592626?
This trial is sponsored by Marengo Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05592626 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05592626's enrollment target sits among peer trials
365 29th of 158 higher than 130 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05669430 · 365 participants · Phase 1
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI